Quaker Wealth Management’s Moderna MRNA Stock Holding History

Quaker Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6	Closed	-$166	–	879
2025 Q2	$166	Buy	+6	New	+$158	﹤0.01%	819

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Quaker Wealth Management's MRNA Position: Q3 2025 in Review

Quaker Wealth Management sold out of Moderna (MRNA) in Q3 2025, closing a stake of 6 shares — an estimated $166 sold.

Quaker Wealth Management first reported a position in MRNA in Q2 2025 and held it in 1 quarter. The position peaked at $166 in Q2 2025. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

Quaker Wealth Management reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
Quaker Wealth Management sold 6 Moderna shares in Q3 2025, an estimated $166.
Quaker Wealth Management first reported a position in Moderna in Q2 2025 and held it in 1 quarter.
Quaker Wealth Management's Moderna position peaked at $166 in Q2 2025.
643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Quaker Wealth Management's 13F filing for Q3 2025, filed 5 Nov 2025.